Friday, February 24, 2012
Clinical evaluation of the role of ceftaroline in the management of community acquired
Clinical evaluation of the role of ceftaroline in the management of community acquired bacterialpneumonia.
Source
University of Texas Health Science Center, San Antonio, Texas.
Abstract
Ceftaroline fosamil (ceftaroline) was recently approved for the treatment of community- acquired pneumonia (CAP) and complicated skin infections. This newly developed cephalosporin possesses a broad spectrum of activity against gram-positive and gram-negative bacteria. Most importantly, ceftaroline demonstrates potent in vitro antimicrobial activity against multi-drug resistant Streptococcus pneumoniae and methicillin-resistant strains of Staphylococcus aureus. In two Phase III, double-blinded, randomized, prospective trials (FOCUS 1 and FOCUS 2), ceftaroline was shown to be non-inferior to ceftriaxone for the treatment of CAP in hospitalized patients. Ceftaroline exhibits low resistance rates and a safety profile similar to that of other cephalosporins. In this review, we will evaluate the pharmacological characteristics, safety, antimicrobial properties, and efficacy of ceftaroline and its applications in the treatment of CAP.
Labels: ceftaroline, community acquired bacterial pneumonia, gram-negative bacteria, Gram-positive, methicillin-resistant strains of Staphylococcus aureus, multi-drug resistant Streptococcus pneumoniae
